Get in touch

Thank you for your interest in DUROLANE.
If you have questions about your health or a medical condition, please consult your physician.

For other questions, including those not covered in the FAQ, please contact us.

PT. KALBE FARMA TBK.
Gedung KALBE
Jl. Let. Jend Suprapto Kav 4
Jakarta 10510, Indonesia

Contact details
T: +62 21 42873888

F: +62 21 4264428

E: durolane@kalbefarma.com

Summary of Indications for Use
DUROLANE (3 mL): Symptomatic treatment of mild to moderate knee or hip osteoarthritis. In addition, DUROLANE has been approved in the EU for the symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, shoulder, elbow, wrist, fingers, and toes.

DUROLANE SJ (1 mL): Symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, elbow, wrist, fingers, and toes.

Both DUROLANE and DUROLANE SJ are also indicated for pain following joint arthroscopy in the presence of osteoarthritis within 3 months of the procedure.

There are no known contraindications.

You should not use DUROLANE if you have infections or skin disease at the injection site. DUROLANE has not been tested in pregnant or lactating women, or children.

Risks can include transient pain, swelling and/or stiffness at the injection site.

Full prescribing information can be found in Product Labeling.

© 2017 Bioventus LLC.
DUROLANE, Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC. NASHA is a registered trademark of Nestlé Skin Health S.A.

© 2017 Bioventus LLC.

^{*First introduced in the European Union in 2001.}

To learn more about DUROLANE or for contact information, please select your location to continue.

Osteoarthritis: The Ongoing Challenges to Manage Pain

https://player.vimeo.com/video/125047428

Osteoarthritis: The Ongoing Challenges to Manage Pain